Back to Results
First PageMeta Content
Immunosuppressants / Infliximab / Abciximab / Forward-looking statement / Medicine / Pharmaceutical industry / Centocor / Monoclonal antibodies / Pharmacology


201 Great Valley Parkway Malvern, Pennsylvania[removed][removed] ! [removed]Fax
Add to Reading List

Document Date: 2013-07-10 15:53:43

Open Document

File Size: 20,92 KB

Share Result on Facebook

City

BUSINESS MALVERN / Parkway Malvern / /

Company

CENTOCOR REACHES AGREEMENT / Eli Lilly and Company / Centocor Inc. / Fujirebio Inc. / /

Country

Germany / Japan / /

Currency

USD / /

Event

M&A / /

Facility

Malvern facility / /

IndustryTerm

biopharmaceutical / healthcare community / monoclonal antibody technology / therapeutic products / /

MedicalCondition

solid tumor cancers / colorectal cancer / Crohn's disease / /

Organization

Securities and Exchange Commission / /

Person

David P. Holveck / Christopher Allman / Bill Newbould / /

/

Position

chief executive officer / Private / /

Product

ReoPro / Retavase / /

ProvinceOrState

Pennsylvania / /

Technology

monoclonal antibody technology / /

URL

wwww.centocor.com / /

SocialTag